1. In Vivo

Financing Quarterly Statistics, Q3 2023

A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2023

 
• By Deanna Kamienski and Maureen Riordan

During Q3, biopharmas brought in an aggregate $23.3bn in financing and device company fundraising totaled $3.6bn; while in vitro diagnostic firms and research tools players raised $649m.

Qstats Image 1
• Source: Alamy

Biopharma financing during the third quarter of 2023 totaled $23.3bn from 238 deals. The debt category made up the greatest proportion (36%) of the aggregate Q3 financing dollars (see Exhibit 1), however, two outlier transactions accounted for 83% of the debt total.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.